Amneal Secures FDA Approval for First Generic Iohexol Injection, Challenging $652 Million Market
核心洞察
Amneal Pharmaceuticals received FDA approval for the first generic version of GE Healthcare's Omnipaque injection, marking a significant milestone in the complex injectable market.
The iohexol injection (300 mg Iodine/mL) is indicated for multiple imaging procedures across various administration routes in adults and pediatric patients two weeks and older.
With U.S. annual sales of approximately $652 million for the 12 months ended September 2025, this first-to-market generic represents substantial market opportunity.
Amneal Pharmaceuticals has secured FDA approval for its iohexol injection (300 mg Iodine/mL), becoming the first company to bring a generic version of GE Healthcare's widely-used Omnipaque injection to market. The approval positions Amneal to capture a significant share of the $652 million annual U.S. market when the product launches in the first quarter of 2026.
The radiographic contrast agent represents a critical tool for healthcare providers, indicated for intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular, and body cavity imaging procedures in adults and pediatric patients two weeks of age and older. According to IQVIA data, U.S. annual sales for iohexol injection reached approximately $652 million for the 12 months ended September 2025.
Complex Injectable Market Entry
"We are very proud to introduce the first-to-market generic version of this critical and widely used injectable contrast agent for patients and healthcare providers," said Arash Dabestani, Pharm.D., Senior Vice President, Institutional at Amneal. "This approval reinforces Amneal's growing leadership in differentiated, complex injectables and our ongoing commitment to improving access to high-quality, affordable medicines."
The FDA approval makes Amneal the first-to-market supplier of this complex injectable, representing a significant achievement in the company's strategy to expand its portfolio of differentiated, complex injectables while improving access to affordable medicines.
Critical Safety Considerations
The product carries a boxed warning highlighting serious safety risks associated with improper administration. Serious adverse reactions, including risk of death, convulsions, seizures, cerebral hemorrhage (搜索), coma, paralysis, arachnoiditis (搜索), acute renal failure (搜索), cardiac arrest (搜索), rhabdomyolysis (搜索), hyperthermia, and brain edema, have been associated with intrathecal administration of iohexol at the wrong iodine concentration.
Reported adverse reactions vary significantly by route of administration:
- Intrathecal use: Headache, nausea, back or neck pain, dizziness
- Intra-arterial or venous use: Chest pain, arrhythmias, blurred vision, photomas, altered taste
- Oral use: Nausea, vomiting, diarrhea, abdominal discomfort
- Body cavity administration: Local pain, swelling, and heat sensation
Market Impact and Launch Timeline
With FDA approval secured, Amneal plans to launch iohexol injection in the first quarter of 2026. The timing allows the company to establish manufacturing and distribution capabilities while preparing healthcare providers for the availability of this more affordable alternative to the branded product.
The approval reinforces Amneal's strategic focus on expanding its presence in differentiated, complex injectables, a segment that typically offers higher barriers to entry and more sustainable competitive advantages compared to traditional generic pharmaceuticals. The company's success in securing first-to-market status for this complex injectable demonstrates its growing capabilities in this specialized area.
Amneal's stock performance reflects the competitive pharmaceutical market environment, with shares trading in a range of $6.68 to $12.12 over the past year. The stock closed at $11.52, down 3.19% following the announcement.